Recent Updates
Recently added Catalysts
INBS Positive Sentiment Score: 80/100

Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Listing Requirement New York, NY

Key Takeaway: Intelligent Bio Solutions Inc. has announced that it has regained compliance with Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share. The company achieved this compliance on February 24, 2023, after being notified of its non-compliance in March 2022. Intelligent Bio Solutions is known for its real-time testing solutions and has recently enhanced its capabilities with the acquisition of Intelligent Fingerprinting Limited. This reinstatement of compliance supports its operational stability in the market.

Market Sentiment Analysis

POSITIVE FACTORS

  • Regained compliance with Nasdaq listing requirements.
  • Minimum bid price requirement met for continued listing.
  • Developing innovative non-invasive testing solutions.
  • Acquisition of Intelligent Fingerprinting enhances product offerings.

Full Press Release Details

Bio Solutions Inc. Regains Compliance with Nasdaq Listing Requirement
York, NY, March 1, 2023 - Intelligent Bio Solutions Inc. ("Intelligent Bio Solutions" or the "Company") (Nasdaq:
INBS), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced that
on February 27, 2023, the Company received a notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq")
informing the Company that it has regained compliance with Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement").
a result, the Company is now in compliance with the Minimum Bid Price Requirement for continued listing and Nasdaq considers the matter
Company was previously notified by Nasdaq on March 17, 2022, that it was not in compliance with the Minimum Bid Price Requirement for
continued listing on the Nasdaq because the Company failed to maintain a minimum bid price per share for its common stock of $1.00 for
30 consecutive business days preceding the date of that notice. To regain compliance, the Company was required to maintain a minimum
bid price of $1.00 per share for at least 10 consecutive trading days. This requirement was met on February 24, 2023.
Bio Solutions Inc. is a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions to customers
globally. With its world-first biosensor platform, Intelligent Bio Solutions is developing and launching diagnostic tests urgently needed
to help people living with chronic disease. In addition, through its recent acquisition of Intelligent Fingerprinting Limited, the Company
is the world leader in the advancement of portable drugs of abuse testing through the analysis of fingerprint sweat. The system is a
platform technology with potential applications in many areas of diagnostics, and its advantages include being non-invasive, hygienic,
fast, and cost-effective. The top-selling product screens for recent use of the most commonly taken drugs in workplace settings; opioids,
cocaine, methamphetamine, and marijuana. Sample collection takes just seconds, with results in ten minutes. Customers include employers
in safety-critical industries such as construction, transport and logistics firms, drug treatment organizations, and UK coroners. A laboratory
confirmation service is also available.
more information, visit http://www.ibs.inc/
of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties.
Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully
develop and commercialize its diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory
approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements
are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by
such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology,
including "believes," "estimates," "anticipates," "expects," "plans," "projects,"
"intends," "potential," "may," "could," "might," "will," "should,"
"approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent
Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this
release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained
in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Strategic Communications

Frequently Asked Questions

What compliance has Intelligent Bio Solutions regained?

The company regained compliance with Nasdaq's Minimum Bid Price Requirement.

When did the company meet the bid price requirement?

Intelligent Bio Solutions met the requirement on February 24, 2023.

What does Intelligent Bio Solutions specialize in?

The company specializes in non-invasive, real-time testing solutions for diagnostics.

What is the primary product offered by the company?

The top product screens for recent drug use, providing results in ten minutes.

How does the company collect drug testing samples?

Samples are collected non-invasively through the analysis of fingerprint sweat.

Last updated: Mar 1, 2023